Fairway Consulting Group Appoints Brennan Clark as Vice President of Executive Search
17 sept. 2024 13h25 HE
|
Fairway Consulting Group
Fairway Consulting Group (FCG) appoints Brennan Clark as Vice President of Executive Search.
Elicio Therapeutics Reports Inducement Grants
17 sept. 2024 08h31 HE
|
Elicio Therapeutics Inc.
BOSTON, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.
17 sept. 2024 06h30 HE
|
ANEW MEDICAL, INC.
ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.
Cybrexa Therapeutics Announces Positive Final Data at ESMO 2024 from Phase 1 Study of Peptide Drug Conjugate CBX-12 in Advanced Solid Tumors
16 sept. 2024 06h30 HE
|
Cybrexa Therapeutics
Cybrexa Therapeutics Announces Positive Final Data at ESMO 2024 from Phase 1 Study of Peptide Drug Conjugate CBX-12 in Advanced Solid Tumors
Certa Therapeutics Announces International Non-Proprietary Name for its First-in-class GPR68 Inhibitor Asengeprast (FT011)
16 sept. 2024 04h00 HE
|
Certa Therapeutics
MELBOURNE, Australia, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with fibrotic diseases, today...
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
15 sept. 2024 03h00 HE
|
23andMe, Inc.
23ME-01473 inhibited tumor growth in a patient-derived xenograft mouse model of non-small cell lung cancer Elevated levels of soluble and tumor-bound ULBP6 confirmed in squamous cell carcinomas and...
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
15 sept. 2024 03h00 HE
|
23andMe, Inc.
23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed partial response Higher tumor expression of CD200 and human...
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
14 sept. 2024 03h00 HE
|
Sutro Biopharma, Inc.
- 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian...
PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology
13 sept. 2024 08h30 HE
|
PRISM MarketView
PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines
13 sept. 2024 08h30 HE
|
Elicio Therapeutics Inc.
BOSTON, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...